Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Dose Escalation, Efficacy, and Safety Study of CLR 131 in Children, Adolescents, and Young Adults With Select Solid Tumors, Lymphoma, and Malignant Brain Tumors

Next Previous
X
Search
Trial Profile

An Open-Label, Dose Escalation, Efficacy, and Safety Study of CLR 131 in Children, Adolescents, and Young Adults With Select Solid Tumors, Lymphoma, and Malignant Brain Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Dec 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Iopofosine I 131 (Primary)
  • Indications Brain cancer; Ewing's sarcoma; Glioma; Hodgkin's disease; Lymphoma; Neuroblastoma; Osteosarcoma; Rhabdomyosarcoma; Sarcoma; Solid tumours
  • Focus Adverse reactions
  • Acronyms CLOVER-2
  • Sponsors Cellectar Biosciences

    • Most Recent Events

    • 19 Dec 2023 According to a Cellectar Biosciences media release, The study is being conducted in up to fifteen leading pediatric cancer centers in North America.
    • 16 May 2023 Status changed from recruiting to active, no longer recruiting.
    • 22 Sep 2022 According to a Cellectar Biosciences media release, the company has been awarded $1.98 million in additional grant funding to expand this trial. The grant was awarded by the National Institute of Health National Cancer Institute (NCI) based upon the initial signals of efficacy in the trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top